Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study

Table 4 Coefficient estimates for each clinical variable in predicting change in mtDNA-CN

Longitudinal Variables	Estimate	SE	95% CI		p-value
BMI	−2.4737	1.8465	−6.0927	1.1453	0.1803
Testosterone	0.3236	0.1541	0.0216	4.4097	0.0357*
SHBG	0.3269	0.2903	−0.2420	0.8959	0.2600
FAI	0.3530	0.3511	−0.3352	1.0412	0.3147
Fasting glucose	1.5686	1.5010	−1.3734	4.5106	0.2960
Fasting insulin	0.0296	0.1470	−0.2584	0.3177	0.8403
HOMA-IR	0.0427	0.1423	−0.2362	0.3217	0.7641
GOT	0.0387	0.2007	−0.3548	0.4322	0.8471
GPT	−0.1001	0.1347	−0.3642	0.1640	0.4575
SBP	−0.9090	1.1083	−3.0813	1.2633	0.4121
DBP	0.0612	0.7854	−1.4780	1.6005	0.9379
hsCRP	−0.0175	0.0466	−0.1089	0.0738	0.7070
8-OHdG	−0.1829	0.1041	−0.3869	0.0211	0.0789
Baseline Variables
Overweight	0.0583	0.1227	−0.1822	0.2988	0.6345
Abdominal obesity	0.0384	0.1392	−0.2343	0.3111	0.7826
Glucose impairment	0.2663	0.1842	−0.0948	0.6275	0.1483
Medication Variables
Non-maximal dose	−0.0421	0.1241	−0.2853	0.2012	0.7346
Compliant	0.1022	0.1300	−0.1526	0.3570	0.4318

p-value < 0.05 is denoted with*; BMI Body mass index, SHBG Sex hormone binding globulin, FAI Free androgen index, HOMA-IR Homeostatic model assessment-insulin resistance, GOT/GPT Glutamic oxaloacetic/pyruvic transaminase, SBP Systolic blood pressure, DBP Diastolic blood pressure, hsCRP High sensitivity C-reactive protein, 8-OHdG 8-hydroxy-2-deoxyguanosine

ISSN: 1477-7827